WallStreetZenWallStreetZen

NASDAQ: HALO
Halozyme Therapeutics Inc Stock Ownership - Who owns Halozyme Therapeutics?

OverviewForecastEarningsRevenueDividendOwnership

Insider buying vs selling

Have Halozyme Therapeutics Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Matthew L. PosardDirector2026-09-163,000$106.83
$320.48kSell
Matthew L. PosardDirector2026-09-164,000$108.99
$435.96kSell
Matthew L. PosardDirector2026-09-168,896$108.04
$961.12kSell
Matthew L. PosardDirector2026-09-163,100$106.13
$329.01kSell
Helen TorleyCEO;Pres2026-09-1120,000$18.41
$368.20kBuy
Helen TorleyCEO;Pres2026-09-114,508$107.55
$484.83kSell
Helen TorleyCEO;Pres2026-09-1115,492$107.15
$1.66MSell
Helen TorleyCEO;Pres2026-09-1020,000$18.41
$368.20kBuy
Helen TorleyCEO;Pres2026-09-105,412$107.58
$582.23kSell
Helen TorleyCEO;Pres2026-09-1014,588$107.01
$1.56MSell

1 of 16

HALO insiders have sold more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when HALO insiders and whales buy or sell their stock.

HALO Shareholders

What type of owners hold Halozyme Therapeutics Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Randal J. Kirk23.47%26,633,924$3.03BInsider
Gregory Ian Frost3.21%3,641,380$414.75MInsider
Helen Torley0.68%767,780$87.45MInsider
Jonathan E. Lim0.63%710,000$80.87MInsider
John Stuart Patton0.36%412,706$47.01MInsider
Kathryn E. Falberg0.32%358,253$40.81MInsider
Robert Engler0.24%273,176$31.11MInsider
Connie Matsui0.16%183,035$20.85MInsider
Kenneth J. Kelley0.16%179,833$20.48MInsider
Michael J. Labarre0.15%173,756$19.79MInsider

1 of 3

HALO vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
HALO0.11%30.25%Net SellingNet Selling
BBIO0.10%56.78%Net SellingNet Selling
CORT0.04%99.96%Net BuyingNet Selling
SMMT0.01%99.99%Net Buying
MDGL0.04%99.96%Net SellingNet Selling
View Top Biotech Stocks

Halozyme Therapeutics Stock Ownership FAQ

Who owns Halozyme Therapeutics?

Halozyme Therapeutics (NASDAQ: HALO) is owned by 0.11% institutional shareholders, 30.25% Halozyme Therapeutics insiders, and 69.64% retail investors. Randal J. Kirk is the largest individual Halozyme Therapeutics shareholder, owning 26.63M shares representing 23.47% of the company. Randal J. Kirk's Halozyme Therapeutics shares are currently valued at $3.03B.

If you're new to stock investing, here's how to buy Halozyme Therapeutics stock.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.